Holen Sie sich die Stockscreener-App
9.32
2.08%
0.19
Handel nachbörslich:
9.32
Schlusskurs vom Vortag:
$9.13
Offen:
$8.95
24-Stunden-Volumen:
416.73K
Relative Volume:
1.17
Marktkapitalisierung:
$305.68M
Einnahmen:
$65.42M
Nettoeinkommen (Verlust:
$-32.96M
KGV:
-7.3386
EPS:
-1.27
Netto-Cashflow:
$-19.87M
1W Leistung:
+4.84%
1M Leistung:
-2.10%
6M Leistung:
-22.91%
1J Leistung:
+28.02%
1-Tages-Spanne:
$7.5625
$9.6788
1-Wochen-Bereich:
$7.5625
$9.6788
52-Wochen-Spanne:
$5.45
$18.98
Neuropace Inc Stock (NPCE) Company Profile
Firmenname
Neuropace Inc
Sektor
Branche
Telefon
(650) 237-2700
Adresse
455 N. BERNARDO AVENUE, MOUNTAIN VIEW
Vergleichen Sie NPCE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NPCE
Neuropace Inc
|
9.32 | 299.45M | 65.42M | -32.96M | -19.87M | -1.27 |
|
ABT
Abbott Laboratories
|
129.40 | 228.03B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
102.50 | 152.09B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
378.95 | 143.98B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.91 | 117.98B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.68 | 45.17B | 5.69B | 1.41B | 577.90M | 6.95 |
Neuropace Inc Stock (NPCE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-01-21 | Eingeleitet | UBS | Buy |
| 2024-03-14 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-01-30 | Eingeleitet | Leerink Partners | Outperform |
| 2023-11-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-08-24 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-02-22 | Eingeleitet | Lake Street | Buy |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-01-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-01-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-11 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-08-18 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-05-17 | Eingeleitet | JP Morgan | Overweight |
| 2021-05-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-05-17 | Eingeleitet | SVB Leerink | Outperform |
| 2021-05-17 | Eingeleitet | Wells Fargo | Overweight |
Alle ansehen
Neuropace Inc Aktie (NPCE) Neueste Nachrichten
NeuroPace, Inc. (NASDAQ:NPCE) Q2 2025 Earnings Call Transcript - Insider Monkey
NeuroPace 2025 Q2 Earnings Revenue Growth Amid Sustained Net Loss - AInvest
NeuroPace stock price target lowered to $15 by Wells Fargo on wider loss forecast - Investing.com South Africa
NeuroPace Expects FDA Submission for Expanded IGE Indication in 2H 2025 - AInvest
NeuroPace Q2 Revenue Hits $23.5M, Up 22% YoY, With Gross Margin at 77.1% - AInvest
NeuroPace Reports Record Revenue and Raises Guidance - TipRanks
Is NeuroPace Inc. in Accumulation Phase NowAI Based High Gain Watchlist Scanner Shared - beatles.ru
NeuroPace Q2 2025 Earnings Call Transcript - MarketBeat
NeuroPace raises 2025 revenue guidance to $94M-$98M as RNS System drives record growth - MSN
NeuroPace: Building a Durable Moat in Epilepsy Treatment with AI-Driven Innovation and Expanding Indications - AInvest
NeuroPace Revenue Jumps 22 Percent in Q2 - Nasdaq
NeuroPace's Q2 2025 Earnings Call: Unraveling Key Contradictions in Growth, Margins, and Strategy - AInvest
NeuroPace, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:NPCE) - Seeking Alpha
Transcript : NeuroPace, Inc., Q2 2025 Earnings Call, Aug 12, 2025 - MarketScreener
NeuroPace's (NPCE) Q2 Performance: A Miss on Earnings, but a Win for the Future? - AInvest
NeuroPace (NPCE) Q2 2025 Earnings Call Transcript - AOL.com
NeuroPace Outpaces Expectations Thanks To RNS System Sales - Finimize
Earnings call transcript: Neuropace Q2 2025 sees revenue rise; stock gains 2.7% - Investing.com
NeuroPace Reports Record Q2 Revenue - Nasdaq
NeuroPace, Inc. (NPCE) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
NeuroPace Inc SEC 10-Q Report - TradingView
NeuroPace Inc.: Q2 Earnings Snapshot - San Francisco Chronicle
Neuropace Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Neuropace earnings missed by $0.04, revenue topped estimates - Investing.com Canada
NeuroPace's Q2 2025 Earnings: A Tale of Two Metrics and the Road to Long-Term Growth - AInvest
NeuroPace Reports Record Q2 2025 Revenue of $23.5 Million, Increases 2025 Guidance - AInvest
NeuroPace Q2 revenue $23.5mln, up 22% YoY, raises FY25 guidance to $94-$98mln. - AInvest
NeuroPace Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance - GlobeNewswire
Can NeuroPace Inc. sustain earnings growthBottom Fishing Opportunity - newsyoung.net
NeuroPace Receives Buy Rating from Lake Street Analyst - AInvest
Is NeuroPace Inc. the Top Chart Pick This WeekTrend Analysis for Safer Trades Gains Popularity - 선데이타임즈
What risks could impact NeuroPace Inc. stock performanceShort Term Momentum Based Trading Strategy - Newser
Applying chart zones and confluence areas to NeuroPace Inc.Free Community Verified Stock Suggestions - Newser
What the charts say about NeuroPace Inc. todayWatchlist Summary for Active Day Traders - Newser
Will NeuroPace Inc. bounce back from current supportHigh Win Rate Strategy with Stop Protection - Newser
Technical signs of recovery in NeuroPace Inc.Daily Market Movers Screener with Filters - Newser
Is a relief rally coming for NeuroPace Inc. holdersFree Triple Return Setup with Risk Control - Newser
News impact scoring models applied to NeuroPace Inc.Swing Trade Timing with Daily Forecast - Newser
NeuroPace (NPCE) to Release Earnings on Tuesday - Defense World
NeuroPace (NPCE) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
What earnings revisions data tells us about NeuroPace Inc.Equity Market Return Forecast Model Update - Newser
Bank of New York Mellon Corp Sells 1,437 Shares of NeuroPace, Inc. (NASDAQ:NPCE) - Defense World
How does NeuroPace Inc. compare to its industry peersTake advantage of unprecedented market momentum - Jammu Links News
What makes NeuroPace Inc. stock price move sharplyExceptional financial outcomes - Jammu Links News
How volatile is NeuroPace Inc. stock compared to the marketUnbelievable profit margins - Jammu Links News
Does NeuroPace Inc. stock perform well during market downturnsGame-changing returns - Jammu Links News
What are the latest earnings results for NeuroPace Inc.Rapid-fire capital growth - Jammu Links News
NeuroPace Inc. Stock Analysis and ForecastGet daily updates on promising stocks - Jammu Links News
What institutional investors are buying NeuroPace Inc. stockGet exclusive access to professional stock picks - Jammu Links News
Is NeuroPace Inc. a growth stock or a value stockFree Stock Market Trend Analysis - Jammu Links News
What are analysts’ price targets for NeuroPace Inc. in the next 12 monthsHigh-octane gains - Jammu Links News
Finanzdaten der Neuropace Inc-Aktie (NPCE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.31%
1.36%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):